Brukinsa® was BeOne Medicines’s largest revenue line in fiscal 2025, bringing in $3.93B of $5.28B (74%).
| Product Name | FY 2020 | FY 2024 | FY 2025 |
|---|---|---|---|
| Brukinsa® | $2.64B | $3.93B | |
| Tevimbra® | $620.84M | $737.30M | |
| Tislelizumab | — | — | |
| Xgeva® | $224.40M | $305.98M | |
| Blincyto® | $74.33M | $104.22M | |
| Kyprolis® | $66.17M | $74.97M | |
| Other | $96.07M | $83.69M | |
| Pobevcy® | $53.51M | $47.40M | |
| Revlimid® | — | — | |
| Vidaza® | — | — | |
| Abraxane® | — | — | |
| Total | $3.78B | $5.28B |
BeOne Medicines brought in $5.28B from its seven revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 39.8% from $3.78B in fiscal 2024. Brukinsa® was the largest at $3.93B (74.4%), ahead of Tevimbra® at $737.30M (14.0%) and Xgeva® at $305.98M (5.8%). The other four revenue lines brought in $310.29M combined.
Compared with fiscal 2024, Brukinsa® grew fastest, up 48.6% to $3.93B. Every revenue line above 2% of revenue grew.
United States was BeOne Medicines’s largest region in fiscal 2025, bringing in $2.84B of $5.28B (54%).
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | $945.55M | $1.95B | $2.84B | |||||||
| U.S | $389.71M | — | — | — | |||||||
| Prc | $840.03M | $1.09B | $1.39B | $1.66B | |||||||
| China | — | — | — | — | |||||||
| Europe- Total Revenue | $48.39M | $122.23M | $359.51M | $609.64M | |||||||
| Other | $10.01M | $28.98M | $78.81M | $171.81M | |||||||
| All Other Countries Except China & The United States Of America | — | — | — | — | |||||||
| Total | $1.29B | $2.19B | $3.78B | $5.28B |
BeOne Medicines brought in $5.28B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 39.8% from $3.78B in fiscal 2024. United States was the largest at $2.84B (53.8%), ahead of Prc at $1.66B (31.4%) and Europe- Total Revenue at $609.64M (11.5%). The remaining region, Other, brought in $171.81M.
Compared with fiscal 2024, Other grew fastest, up 118.0% to $171.81M. Every region above 2% of revenue grew.
BeOne Medicines stopped reporting U.S as a separate region after fiscal 2022, when it brought in $389.71M.
Tislelizumab was BeOne Medicines’s largest revenue line in fiscal 2021, bringing in $591.49M of $1.14B (52%).
| Counterparty Name | FY 2021 |
|---|---|
| Tislelizumab | $591.49M |
| Novartis | $542.30M |
| Ociperlimab | $4.48M |
| Total | $1.14B |
BeOne Medicines brought in $1.14B from its three revenue lines in fiscal 2021, the year ended December 31, 2021. Tislelizumab was the largest at $591.49M (52.0%), ahead of Novartis at $542.30M (47.6%) and Ociperlimab at $4.48M (0.4%).
BeOne Medicines (ONC) reports its revenue by product name, by geography and by counterparty name. In fiscal 2025, Brukinsa® was its largest revenue line, bringing in $3.93B (74.4% of the total), followed by Tevimbra® at $737.30M (14.0%).
Brukinsa® was BeOne Medicines' largest revenue line in fiscal 2025, bringing in $3.93B, or 74.4% of the $5.28B total across its seven revenue lines.
United States was BeOne Medicines' largest region in fiscal 2025, bringing in $2.84B, or 53.8% of the $5.28B total across its four regions.
Among BeOne Medicines' revenue lines that make up at least 2% of revenue, Brukinsa® grew fastest in fiscal 2025, up 48.6% from $2.64B to $3.93B.
Every figure comes from BeOne Medicines' annual financial filings, as reported. Each line keeps the name BeOne Medicines gives it, and years follow its fiscal calendar.
BeOne Medicines' revenue by product name goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.